ArticleDiscover oncology2025
Integrative bioinformatics analysis and elastic network modeling elucidate the role of cellular senescence in meningioma recurrence.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCellular senescence is intimately tied to tumorigenesis and progression, yet its exploration in meningiomas remains inadequate. In this study, we aim to unravel the role of cellular senescence-associated genes (CSA-genes) in meningioma recurrence and identify potential diagnostic markers and therapeutic targets.
methodsWe analyzed GSE136661 and GSE173825 datasets to identify CSA-signature genes through differential expression analysis, weighted gene co-expression network analysis, protein-protein interaction network construction, and elastic net regression modeling. Functional enrichment, immune cell infiltration using CIBERSORT, and transcription factor prediction were performed. Potential drugs were screened using Enrichr database.
resultsA total of 1827 differentially expressed genes (DEGs) were identified, among which 48 were cell senescence-associated differentially expressed genes (CSA-DEGs). Four key CSA-signature genes (CDK1, FOXM1, MYBL2, and BIRC5) were discovered by integrating elastic net regression and network algorithms. The elastic net model demonstrated strong classification performance with an area under the curve (AUC) of 0.816 in distinguishing recurrent meningiomas. Recurrent tumors exhibited significant immune heterogeneity, including increased neutrophils and M0 macrophages (p = 0.007), and CSA-genes were significantly correlated with immune infiltration and checkpoint molecules such as VSIR (p < 0.05). Transcription factor E2F1 was identified as a potential regulator of CSA-signature genes. Drug screening highlighted Dasatinib and Rapamycin as promising candidates with notable anti-meningioma potential.
conclusionOur findings highlight crucial genes and pathways in meningioma recurrence, introducing novel therapeutic candidates. These findings pave new avenues for further elucidating meningioma recurrence mechanisms and developing innovative treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.